相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M. R. Sydes et al.
ANNALS OF ONCOLOGY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
David Y. Takeda et al.
CELL (2018)
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Srinivas R. Viswanathan et al.
CELL (2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
Michael T. Schweizer et al.
PLOS ONE (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
Chengfei Liu et al.
MOLECULAR CANCER THERAPEUTICS (2017)
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer
Dong Han et al.
ONCOTARGET (2017)
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Bram De laere et al.
EUROPEAN UROLOGY (2017)
Darolutamide (ODM-201) for the treatment of prostate cancer
Neal D. Shore
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions
Kush Dalal et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth
Jacob Kach et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
Ping Mu et al.
SCIENCE (2017)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Sheng Yu Ku et al.
SCIENCE (2017)
Emerging Variants of Castration-Resistant Prostate Cancer
Panagiotis J. Vlachostergios et al.
CURRENT ONCOLOGY REPORTS (2017)
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
Min Zou et al.
CANCER DISCOVERY (2017)
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
Daisuke Obinata et al.
CANCERS (2017)
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli et al.
CLINICAL CANCER RESEARCH (2017)
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery et al.
CLINICAL CANCER RESEARCH (2016)
Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
Minoru Kato et al.
CLINICAL CANCER RESEARCH (2016)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic
Yusuke Imamura et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
Samanta Salvi et al.
ONCOTARGET (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
"Getting From Here to There"-Mechanisms and Limitations to the Activation of the Androgen Receptor in Castration-Resistant Prostate Cancer
Nima Sharifi et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
S. Salvi et al.
BRITISH JOURNAL OF CANCER (2015)
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
Duo Xu et al.
CANCER RESEARCH (2015)
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
Chengfei Liu et al.
CANCER RESEARCH (2015)
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Yoshiaki Yamamoto et al.
CLINICAL CANCER RESEARCH (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Paul Toren et al.
EUROPEAN UROLOGY (2015)
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
Theodoros Karantanos et al.
EUROPEAN UROLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
NAR Breakthrough Article Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Siu Chiu Chan et al.
NUCLEIC ACIDS RESEARCH (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines
Vidya P. Ramamurthy et al.
ONCOTARGET (2015)
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Shusuke Akamatsu et al.
CELL REPORTS (2015)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Eddy J. Chen et al.
CLINICAL CANCER RESEARCH (2015)
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
Ziyang Yu et al.
CLINICAL CANCER RESEARCH (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
Kathryn E. Ware et al.
ENDOCRINE-RELATED CANCER (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of the androgen receptor splicing in prostate cancer cells
L. L. Liu et al.
ONCOGENE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Bo Cao et al.
ONCOTARGET (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
Takashi Kobayashi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control
Yue Yu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Christian Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2013)
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
Michael D. Nyquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
Siu Chiu Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
Y. Li et al.
ONCOGENE (2012)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
Yingming Li et al.
CANCER RESEARCH (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate
Charles C. Guo et al.
HUMAN PATHOLOGY (2011)
ERG gene rearrangements are common in prostatic small cell carcinomas
Tamara L. Lotan et al.
MODERN PATHOLOGY (2011)
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin
Sean R. Williamson et al.
MODERN PATHOLOGY (2011)
Differential transformation capacity of Src family kinases during the initiation of prostate cancer
Houjian Cai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Snapshot of the Expression Signature of Androgen Receptor Splicing Variants and Their Distinctive Transcriptional Activities
Rong Hu et al.
PROSTATE (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)